Traumakine Research Collaboration and DoD Grant
Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) Faron Announces Traumakine Research Collaboration and DoD Grant Press release, 13 August 2024 at 7:00 a.m. BST / 9:00 a.m. EEST TURKU, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company with its lead immune oncology program bexmarilimab, also pursuing induction of CD73 for organ protection, announces it has joined a research consortium that has received a Department of Defense (DoD) Grant to investigate the use of intravenous interferon